Article
TMB or not TMB as a biomarker: That is the question.
Critical reviews in oncology/hematology - 1 Jul 2021
Addeo Alfredo, Friedlaender Alex, Banna Giuseppe L, Weiss Glen J
Abstract excerpt
Immune checkpoint inhibitors (ICIs) have revolutionized the landscape of therapeutic options for many cancers. These treatments have demonstrated improved efficacy and often a more favourable toxicity profile compared to standard cytotoxic chemotherapy. There are considerable differences among responders, with some patients experiencing durable long-term disease control and even remission. Given this variability,...
Topics
Join the communities discussing this publication.